Research ArticleArticle
Characterization of Thrombin-Bound Dabigatran Effects on Protease-Activated Receptor-1 Expression and Signaling In Vitro
Buxin Chen, Antonio G. Soto, Luisa J. Coronel, Ashley Goss, Joanne van Ryn and JoAnn Trejo
Molecular Pharmacology July 2015, 88 (1) 95-105; DOI: https://doi.org/10.1124/mol.114.096446
Buxin Chen
Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, California (B.C., A.G.C., L.J.C., J.T.); Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut (A.G.); and Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharma Gmbh, Biberach, Germany (J.R.)
Antonio G. Soto
Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, California (B.C., A.G.C., L.J.C., J.T.); Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut (A.G.); and Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharma Gmbh, Biberach, Germany (J.R.)
Luisa J. Coronel
Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, California (B.C., A.G.C., L.J.C., J.T.); Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut (A.G.); and Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharma Gmbh, Biberach, Germany (J.R.)
Ashley Goss
Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, California (B.C., A.G.C., L.J.C., J.T.); Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut (A.G.); and Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharma Gmbh, Biberach, Germany (J.R.)
Joanne van Ryn
Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, California (B.C., A.G.C., L.J.C., J.T.); Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut (A.G.); and Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharma Gmbh, Biberach, Germany (J.R.)
JoAnn Trejo
Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, California (B.C., A.G.C., L.J.C., J.T.); Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut (A.G.); and Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharma Gmbh, Biberach, Germany (J.R.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Dabigatran and PAR1 Function
Buxin Chen, Antonio G. Soto, Luisa J. Coronel, Ashley Goss, Joanne van Ryn and JoAnn Trejo
Molecular Pharmacology July 1, 2015, 88 (1) 95-105; DOI: https://doi.org/10.1124/mol.114.096446
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement